TITLE:
Frequency of Epidermal Growth Factor Mutation Status and Its Effect on Outcome of Patients with Adenocarcinoma of the Lung
AUTHORS:
Hanan E. Shafik, Salem H. Al-Shemarri, Fahed Al-Enezi, Mohamed Ashour, Eman Khalaf, Ahmed I. Al-Khodary
KEYWORDS:
Adenocarcinoma, EGFR, NSCLC, Outcome
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.5 No.11,
September
26,
2014
ABSTRACT: he frequency of EGFR mutations is ethnicity-dependent, with a
higher proportion in Asian population than in whites. The prevalence of these
mutations among Arab patients is unknown. The objective of this study was to
report the frequency and spectrum of EGFR mutations in our population with lung
adenocarcinoma, and the effect of this mutation on treatment outcome. Tumor specimens
from 81 patients histological diagnosed as NSCLC adenocarcinoma were reviewed
by our local pathologist and then sent to Lab 21 London, UK. Samples were
tested for 28 mutations in EGFR gene. Positive patients received TKI and
negative patients received chemotherapy. Data were collected and
retrospectively analyzed to determine frequency and spectrum of EGFR positivity.
Patients were followed for time to progression (TTP) and overall survival (OS).
Overall frequency of EGFR mutation was 37%; Del 19 (46.6%), L858R (40%), D719x and insertion 20 (6.7%) for each. Females
and nonsmokers exhibited a statistically significant higher EGFR positivity (P
= 0.003, 0.059) respectively. Overall response rate (ORR) was 76.6% and 43% in EGFR positive and negative cases
respectively (P = 0.002). There was a statistically significant difference in
TTP and OS between EGFR positive and negative patients (P = 0.035 and 0.039
respectively). Arab patients exhibit an EGFR mutation pattern that is closer to
Asian population. EGFR gene mutation subtypes are the same as that reported
worldwide. A statistically significant TTP and OS benefit was noticed in EGFR
positive patients compared to EGFR negative cases.